ProKidney Corp. Class A (PROK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Nephrologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 45/100 (MEDIUM), 6.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
- Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
- ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
- ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
- ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
- ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
- ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
- ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ProKidney Corp. Class A.
Full PROK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.